Targeted Therapies for Head and Neck Cancer
Author Information
Author(s): Lisa A. Elferink, Vicente A. Resto
Primary Institution: University of Texas Medical Branch
Hypothesis
The interplay between EGFR and other receptor tyrosine kinases contributes to therapeutic resistance in head and neck cancer.
Conclusion
Targeted therapies that block EGFR, Met, and IGF-1R signaling in head and neck cancers show promising results, but predicting patient response remains challenging.
Supporting Evidence
- EGFR gene amplification is linked to poor patient survival and treatment resistance.
- Targeting multiple receptor pathways may improve treatment outcomes in head and neck cancer.
- Resistance mechanisms include receptor mutations and cross-talk between signaling pathways.
Takeaway
This study looks at how certain cancer treatments work for head and neck cancer and why some patients might not respond well to them.
Methodology
The review discusses various receptor tyrosine kinases and their roles in head and neck cancer, focusing on EGFR, Met, and IGF-1R.
Limitations
The study highlights the difficulty in predicting which patients will benefit from targeted therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website